Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway
Xufen Zheng, Yuxiang Luo, Yangjie Xiong, Xiaoxiao Liu, Chunling Zeng, Xiaojing Lu, Xiaofang Wang, Yumei Cheng, Simin Wang, Haoqi Lan, Kai Wang, Zhonghui Weng, Wenbo Bi, Xinxin Gan, Xiaona Jia, Linhui Wang, Yuexiang Wang · 2023
Read Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway by Xufen Zheng, Yuxiang Luo, Yangjie Xiong, Xiaoxiao Liu, Chunling Zeng, Xiaojing Lu, Xiaofang Wang, Yumei Cheng, Simin Wang, Haoqi Lan, Kai Wang, Zhonghui Weng, Wenbo Bi, Xinxin Gan, Xiaona Jia, Linhui Wang, Yuexiang Wang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10711831.txt.
Description
A large research team reports in 2023 that turning off one gene in tumor cells can make cancer drugs work better. The gene, SETD2, is often changed in cancers treated with drugs that free the immune system to attack. The team asked what loss of the gene does inside a tumor and why some patients gain lasting benefit.
In mouse tumors, loss of the gene drew in many more killer T cells and sharpened the display of tumor flags on cell surfaces. The change lowered a brake protein and switched on a signal path that raised those flags and cell lures. Blood tests and patient data backed the mouse work. The authors propose the gene's loss as a sign that helps doctors pick who may gain from these drugs.
Catalog record
| CREATOR | Xufen Zheng, Yuxiang Luo, Yangjie Xiong, Xiaoxiao Liu, Chunling Zeng, Xiaojing Lu, Xiaofang Wang, Yumei Cheng, Simin Wang, Haoqi Lan, Kai Wang, Zhonghui Weng, Wenbo Bi, Xinxin Gan, Xiaona Jia, Linhui Wang, Yuexiang Wang |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |